首页> 美国卫生研究院文献>The Oncologist >Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group

【2h】

Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group

机译：国际mRCC数据库联合会风险小组对一线舒尼替尼一线透明细胞转移性肾细胞癌（mRCC）患者的临床疗效进行了真实世界评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (IMDC) risk groups are important when considering therapeutic options for first‐line treatment.

机译：在考虑一线治疗的治疗选择时，国际转移性肾细胞癌（mRCC）数据库联合会（IMDC）风险组很重要。

著录项

期刊名称 The Oncologist
作者
Marie‐France Savard; J. Connor Wells; Jeffrey Graham; Shaan Dudani; John A. Steinharter; Bradley A. McGregor; Frede Donskov; Georg A. Bjarnason; Ulka N. Vaishampayan; Aaron R. Hansen; Marco A.J. Iafolla; Giovanni Zanotti; Lynn Huynh; Rose Chang; Mei S. Duh; Daniel Y.C. Heng;
展开▼
作者单位

展开▼
年(卷),期 2020(25),5
年度 2020
页码 -1
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
International Metastatic Renal Cell Carcinoma Database Consortium; Metastatic renal cell carcinoma; Sunitinib; Real‐world clinical outcome; Overall survival;

机译：国际转移性肾细胞癌数据库联盟;转移性肾细胞癌;舒尼替尼;真实临床结果;总生存期;

相似文献

外文文献
中文文献
专利

1. 索拉非尼与舒尼替尼一线治疗中国转移性肾细胞癌患者的疗效、安全性和生活质量的比较 [J] . Wen Cai, Wen Kong, Baijun Dong, 癌症（英文版） . 2018,第003期
2. Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group [J] . Savard Marie‐France, Wells J. Connor, Graham Jeffrey, The oncologist . 2020,第5期

机译：国际MRCC数据库联盟危险集团综合孙尼替尼患者综合细胞转移性肾细胞癌（MRCC）的临床结果对临床结果的真实评价
3. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group [J] . Marie-France Savard, Aaron R. Hansen, Marco A.J. Iafolla, The oncologist . 2020,第5期

机译：国际MRCC数据库联盟危险集团综合孙尼替尼患者综合细胞转移性肾细胞癌（MRCC）的临床结果对临床结果的真实评价
4. Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel YC Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46 Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium [J] . Conforti Fabio, Pala Laura, Bagnardi Vincenzo, European urology . 2019,第2期

机译：回复Jeffrey Graham，Omar Abdel-Rahman，Toni K. Choueiri和Daniel YC Heng的信Re：Fabio Conforti，Laura Pala，Vincenzo Bagnardi，等。癌症免疫治疗疗效和患者性别：系统审查和荟萃分析。柳叶葡萄甘蓝2018; 19：737-46性别转移性肾细胞癌的结果：国际MRCC数据库联盟的对比结果
5. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
6. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
7. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group [O] . Brian I Rini, Thomas E. Hutson, Robert A. Figlin, -1

机译：舒尼替尼治疗转移性肾细胞癌患者：根据国际转移性肾细胞癌数据库联合会风险组的临床结果
8. PCN22 CLINICAL HETEROGENEITY AMONG FIRST-LINE SUNITINIB PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) CATEGORIZED AS INTERMEDIATE RISK (IR) GROUP ACCORDING TO THE INTERNATIONAL MRCC DATABASE CONSORTIUM (IMDC) RISK MODEL [O] . L. Huynh, J.C. Wells, J. Graham, 2019

机译：PCN22根据国际MRCC数据库联盟（IMDC）风险模型，将一线仙硝尼患者（MRCC）分类为中间风险（IR）组的临床异质性

Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group

摘要

著录项

相似文献

相关主题

期刊订阅